<p>在全球市场波动的一周中，由于关税不确定性和经济信号混杂，美国股市收盘下跌，标准普尔 500 指数小幅下滑 0.24%。尽管面临这些挑战，小型股通常在市场情绪波动时提供独特的增长机会。在这种环境下，识别小型股领域中未被发现的潜力股需要关注那些在经济环境变化中展现出韧性和潜力的公司。</p>
<h3>基本面强劲的十大未被发现的潜力股</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>负债权益比</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>健康评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darya-Varia Laboratoria</td>
<td>NA</td>
<td>1.44%</td>
<td>-11.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Quemchi</td>
<td>0.66%</td>
<td>82.67%</td>
<td>21.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Wilson Bank Holding</td>
<td>NA</td>
<td>7.87%</td>
<td>8.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Ovostar Union</td>
<td>0.01%</td>
<td>10.19%</td>
<td>49.85%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Aesler Grup Internasional</td>
<td>NA</td>
<td>-17.61%</td>
<td>-40.21%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>National General Insurance (P.J.S.C.)</td>
<td>NA</td>
<td>11.69%</td>
<td>30.36%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Watt's</td>
<td>70.56%</td>
<td>7.69%</td>
<td>-0.53%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Hollyland (China) Electronics Technology</td>
<td>3.46%</td>
<td>13.95%</td>
<td>11.27%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Al-Deera Holding Company K.P.S.C</td>
<td>6.11%</td>
<td>51.44%</td>
<td>59.77%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Central Cooperative Bank AD</td>
<td>4.88%</td>
<td>37.94%</td>
<td>537.05%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们筛选出的 4699 只股票的完整列表，均为基本面强劲的未被发现的潜力股。</p>
<p>让我们回顾一些筛选股票中的显著选择。</p>
<h2>OrbusNeich 医疗集团控股（SEHK:6929）</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> OrbusNeich 医疗集团控股有限公司是一家投资控股公司，专注于心脏病和外周血管疾病的医疗设备的研究、开发、制造和营销，市场覆盖日本、欧洲和美国，市值为 29 亿港元。</p>
<p><strong>运营：</strong> 该公司从其外科和医疗设备部门产生的收入为 1.5137 亿美元。</p>
<p>OrbusNeich 医疗集团控股在医疗设备领域是一家显著的参与者，过去一年盈利增长 8.6%，超过行业的-4.3%。该公司目前的交易价格比其估计的公允价值低 78.2%，并且现金超过总债务，显示出良好的财务基础。最近的进展包括召开特别股东大会，旨在修订股份发行和回购的授权，可能会影响未来的资本结构。预计盈利年增长率为 13.83%，为寻求被低估的医疗创新机会的投资者提供了引人注目的前景。</p>
<ul>
<li>点击这里了解 OrbusNeich 医疗集团控股的细节分析健康报告。</li>
<li>了解 OrbusNeich 医疗集团控股的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/95005aef-37fc-410f-afe4-96444d1d719e/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/95005aef-37fc-410f-afe4-96444d1d719e/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:6929 截至 2025 年 2 月的盈利和收入增长</p>
<h2>智洋创新科技（SHSE:688191）</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 智洋创新科技有限公司是一家总部位于中国的人工智能公司，市值为 30.8 亿人民币。</p>
<p><strong>运营：</strong> 智洋创新科技主要通过其人工智能解决方案产生收入。公司的财务表现以 45% 的毛利率为亮点，表明在管理生产成本相对于销售方面的效率。</p>
<p>智洋创新科技在科技领域是一家较小的参与者，过去一年盈利增长 27.7%，超过了更广泛的电气行业的 1.1%。尽管过去五年经历了年盈利下降 26.3% 的挑战，但最近的表现突显了其韧性和复苏潜力。该公司能够舒适地覆盖其利息义务，并且相对于其总债务保持健康的现金状况，债务权益比在五年内从零上升至 11.3%。凭借正的自由现金流和高质量的盈利，智洋似乎在其行业内有进一步探索的潜力。</p>
<ul>
<li>点击这里访问我们的完整健康分析报告，以了解智洋创新科技的动态。</li>
<li>查看我们的历史表现报告，以获取智洋创新科技过去表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6aebebee-9140-4380-8187-1b22dfe740b9/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6aebebee-9140-4380-8187-1b22dfe740b9/chart/debt-equity-history-analysis"/></p>
<p>SHSE:688191 截至 2025 年 2 月的负债权益比</p>
<h2>Kamei（TSE:8037）</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Kamei Corporation 是一家在日本及国际上运作的一般贸易公司，市值为 600.2 亿日元。</p>
<p><strong>运营：</strong> Kamei Corporation 的主要收入来源包括 2791 亿日元的能源业务和 867.8 亿日元的海外/贸易业务，其次是 752.9 亿日元的汽车相关业务。公司的净利润率反映了其在这些多元化领域有效管理成本的能力。</p>
<p>Kamei 在贸易分销商领域是一家较小的参与者，过去一年盈利增长 14.9%，超过了行业的 3.4%。该公司目前的交易价格比其估计的公允价值低 93.1%，暗示潜在的低估。在过去五年中，Kamei 的负债权益比从 51% 改善至 28.9%，显示出更好的财务健康和降低的杠杆风险。最近，Kamei 宣布了一项 40 亿日元的股份回购计划，以提升股东价值并适应市场变化；这一举措反映了对未来前景的信心和资本管理的战略灵活性。</p>
<ul>
<li>通过我们的综合健康报告深入了解 Kamei 的复杂性。</li>
<li>通过访问我们的历史表现报告评估 Kamei 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc868fea-bc7d-4c3b-ad20-a91f73bb57cd/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc868fea-bc7d-4c3b-ad20-a91f73bb57cd/chart/debt-equity-history-analysis"/></p>
<p>TSE:8037 截至 2025 年 2 月的债务与股本比率</p>
<h2>总结</h2>
<ul>
<li>点击这里解锁我们包含 4699 个具有强大基本面的未被发现的投资机会的综合列表。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，您可以轻松监控所有股票的关键指标。</li>
<li>使用 Simply Wall St 应用程序提升您的投资能力，享受跨越每个大洲的市场情报的免费访问。</li>
</ul>
<h2>寻找其他投资？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>

业聚医疗

智洋创新

8037

<p>在全球市场波动的一周中，美国股市小幅下跌，标准普尔 500 指数下跌了 0.24%。尽管如此，小型股仍然呈现出增长机会。值得注意的小型公司包括业聚医疗、智洋创新和亀井株式会社，这些公司都展现出强劲的基本面和增长潜力。业聚医疗专注于医疗设备，智洋创新专注于人工智能解决方案，而亀井株式会社则作为一家综合贸易公司运营。每家公司都展现出韧性和良好的财务健康，使其成为寻求被低估机会的投资者的有吸引力的选择</p>

<p>In a week marked by global market fluctuations, U.S. stocks ended lower amid tariff uncertainties and mixed economic signals, with the S&amp;P 500 Index experiencing a slight decline of 0.24%. Despite these challenges, small-cap stocks often present unique opportunities for growth, particularly when broader market sentiment is volatile. In this environment, identifying undiscovered gems within the small-cap sector requires an eye for companies that demonstrate resilience and potential amidst shifting economic landscapes.</p>
<div class="lb-trans"><p>在全球市场波动的一周中，由于关税不确定性和经济信号混杂，美国股市收盘下跌，标准普尔 500 指数小幅下滑 0.24%。尽管面临这些挑战，小型股通常在市场情绪波动时提供独特的增长机会。在这种环境下，识别小型股领域中未被发现的潜力股需要关注那些在经济环境变化中展现出韧性和潜力的公司。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals</h3>
<div class="lb-trans"><h3>基本面强劲的十大未被发现的潜力股</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darya-Varia Laboratoria</td>
<td>NA</td>
<td>1.44%</td>
<td>-11.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Quemchi</td>
<td>0.66%</td>
<td>82.67%</td>
<td>21.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Wilson Bank Holding</td>
<td>NA</td>
<td>7.87%</td>
<td>8.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Ovostar Union</td>
<td>0.01%</td>
<td>10.19%</td>
<td>49.85%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Aesler Grup Internasional</td>
<td>NA</td>
<td>-17.61%</td>
<td>-40.21%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>National General Insurance (P.J.S.C.)</td>
<td>NA</td>
<td>11.69%</td>
<td>30.36%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Watt's</td>
<td>70.56%</td>
<td>7.69%</td>
<td>-0.53%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Hollyland (China) Electronics Technology</td>
<td>3.46%</td>
<td>13.95%</td>
<td>11.27%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Al-Deera Holding Company K.P.S.C</td>
<td>6.11%</td>
<td>51.44%</td>
<td>59.77%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Central Cooperative Bank AD</td>
<td>4.88%</td>
<td>37.94%</td>
<td>537.05%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>负债权益比</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>健康评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darya-Varia Laboratoria</td>
<td>NA</td>
<td>1.44%</td>
<td>-11.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Quemchi</td>
<td>0.66%</td>
<td>82.67%</td>
<td>21.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Wilson Bank Holding</td>
<td>NA</td>
<td>7.87%</td>
<td>8.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Ovostar Union</td>
<td>0.01%</td>
<td>10.19%</td>
<td>49.85%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Aesler Grup Internasional</td>
<td>NA</td>
<td>-17.61%</td>
<td>-40.21%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>National General Insurance (P.J.S.C.)</td>
<td>NA</td>
<td>11.69%</td>
<td>30.36%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Watt's</td>
<td>70.56%</td>
<td>7.69%</td>
<td>-0.53%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Hollyland (China) Electronics Technology</td>
<td>3.46%</td>
<td>13.95%</td>
<td>11.27%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Al-Deera Holding Company K.P.S.C</td>
<td>6.11%</td>
<td>51.44%</td>
<td>59.77%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Central Cooperative Bank AD</td>
<td>4.88%</td>
<td>37.94%</td>
<td>537.05%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 4699 stocks from our Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>点击这里查看我们筛选出的 4699 只股票的完整列表，均为基本面强劲的未被发现的潜力股。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>让我们回顾一些筛选股票中的显著选择。</p>
</div><h2>OrbusNeich Medical Group Holdings (SEHK:6929)</h2>
<div class="lb-trans"><h2>OrbusNeich 医疗集团控股（SEHK:6929）</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> OrbusNeich Medical Group Holdings Limited is an investment holding company that focuses on the research, development, manufacturing, and marketing of medical devices for coronary and peripheral vascular diseases across various global markets including Japan, Europe, and the United States with a market cap of HK$2.90 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> OrbusNeich 医疗集团控股有限公司是一家投资控股公司，专注于心脏病和外周血管疾病的医疗设备的研究、开发、制造和营销，市场覆盖日本、欧洲和美国，市值为 29 亿港元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of $151.37 million from its surgical and medical equipment segment.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司从其外科和医疗设备部门产生的收入为 1.5137 亿美元。</p>
</div><p>OrbusNeich Medical Group Holdings, a notable player in the medical equipment sector, has demonstrated robust financial health with earnings growing by 8.6% over the past year, outpacing the industry's -4.3%. The company is trading at a significant discount of 78.2% below its estimated fair value and maintains more cash than total debt, indicating solid financial footing. Recent developments include a special shareholders meeting aimed at revising mandates for share issuance and repurchase, potentially impacting future capital structure. With earnings forecasted to grow annually by 13.83%, it presents intriguing prospects for investors seeking undervalued opportunities in healthcare innovation.</p>
<div class="lb-trans"><p>OrbusNeich 医疗集团控股在医疗设备领域是一家显著的参与者，过去一年盈利增长 8.6%，超过行业的-4.3%。该公司目前的交易价格比其估计的公允价值低 78.2%，并且现金超过总债务，显示出良好的财务基础。最近的进展包括召开特别股东大会，旨在修订股份发行和回购的授权，可能会影响未来的资本结构。预计盈利年增长率为 13.83%，为寻求被低估的医疗创新机会的投资者提供了引人注目的前景。</p>
</div><ul>
<li>Click here to discover the nuances of OrbusNeich Medical Group Holdings with our detailed analytical health report.</li>
<li>Learn about OrbusNeich Medical Group Holdings' historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里了解 OrbusNeich 医疗集团控股的细节分析健康报告。</li>
<li>了解 OrbusNeich 医疗集团控股的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/95005aef-37fc-410f-afe4-96444d1d719e/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/95005aef-37fc-410f-afe4-96444d1d719e/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:6929 Earnings and Revenue Growth as at Feb 2025</p>
<div class="lb-trans"><p>SEHK:6929 截至 2025 年 2 月的盈利和收入增长</p>
</div><h2>Zhiyang Innovation Technology (SHSE:688191)</h2>
<div class="lb-trans"><h2>智洋创新科技（SHSE:688191）</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Zhiyang Innovation Technology Co., Ltd. is an artificial intelligence company based in China with a market capitalization of CN¥3.08 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 智洋创新科技有限公司是一家总部位于中国的人工智能公司，市值为 30.8 亿人民币。</p>
</div><p><strong>Operations:</strong> Zhiyang Innovation Technology generates revenue primarily through its artificial intelligence solutions. The company's financial performance is highlighted by a gross profit margin of 45%, indicating efficiency in managing production costs relative to sales.</p>
<div class="lb-trans"><p><strong>运营：</strong> 智洋创新科技主要通过其人工智能解决方案产生收入。公司的财务表现以 45% 的毛利率为亮点，表明在管理生产成本相对于销售方面的效率。</p>
</div><p>Zhiyang Innovation Technology, a smaller player in the tech landscape, has shown significant earnings growth of 27.7% over the past year, outpacing the broader Electrical industry at 1.1%. Despite a challenging five-year period with annual earnings dropping by 26.3%, recent performance highlights resilience and potential for recovery. The company is comfortably covering its interest obligations and maintains a healthy cash position relative to its total debt, which has risen to an 11.3% debt-to-equity ratio from zero over five years. With positive free cash flow and high-quality earnings, Zhiyang seems poised for further exploration within its sector.</p>
<div class="lb-trans"><p>智洋创新科技在科技领域是一家较小的参与者，过去一年盈利增长 27.7%，超过了更广泛的电气行业的 1.1%。尽管过去五年经历了年盈利下降 26.3% 的挑战，但最近的表现突显了其韧性和复苏潜力。该公司能够舒适地覆盖其利息义务，并且相对于其总债务保持健康的现金状况，债务权益比在五年内从零上升至 11.3%。凭借正的自由现金流和高质量的盈利，智洋似乎在其行业内有进一步探索的潜力。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Zhiyang Innovation Technology.</li>
<li>Review our historical performance report to gain insights into Zhiyang Innovation Technology's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整健康分析报告，以了解智洋创新科技的动态。</li>
<li>查看我们的历史表现报告，以获取智洋创新科技过去表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6aebebee-9140-4380-8187-1b22dfe740b9/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/6aebebee-9140-4380-8187-1b22dfe740b9/chart/debt-equity-history-analysis"/></p>
<p>SHSE:688191 Debt to Equity as at Feb 2025</p>
<div class="lb-trans"><p>SHSE:688191 截至 2025 年 2 月的负债权益比</p>
</div><h2>Kamei (TSE:8037)</h2>
<div class="lb-trans"><h2>Kamei（TSE:8037）</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Kamei Corporation functions as a general trading company both in Japan and internationally, with a market capitalization of ¥60.02 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Kamei Corporation 是一家在日本及国际上运作的一般贸易公司，市值为 600.2 亿日元。</p>
</div><p><strong>Operations:</strong> The primary revenue streams for Kamei Corporation include the Energy Business at ¥279.10 billion and the Overseas/Trade Business at ¥86.78 billion, followed by the Automotive Related Business contributing ¥75.29 billion. The company’s net profit margin reflects its ability to manage costs effectively across these diverse segments.</p>
<div class="lb-trans"><p><strong>运营：</strong> Kamei Corporation 的主要收入来源包括 2791 亿日元的能源业务和 867.8 亿日元的海外/贸易业务，其次是 752.9 亿日元的汽车相关业务。公司的净利润率反映了其在这些多元化领域有效管理成本的能力。</p>
</div><p>Kamei, a smaller player in the trade distributors sector, has shown impressive earnings growth of 14.9% over the past year, outpacing the industry's 3.4%. The company is trading at a significant discount of 93.1% below its estimated fair value, suggesting potential undervaluation. Over five years, Kamei's debt to equity ratio improved from 51% to 28.9%, indicating better financial health and reduced leverage risks. Recently, Kamei announced a share repurchase program for ¥4 billion to enhance shareholder value and adapt to market changes; this move reflects confidence in its future prospects and strategic flexibility in capital management.</p>
<div class="lb-trans"><p>Kamei 在贸易分销商领域是一家较小的参与者，过去一年盈利增长 14.9%，超过了行业的 3.4%。该公司目前的交易价格比其估计的公允价值低 93.1%，暗示潜在的低估。在过去五年中，Kamei 的负债权益比从 51% 改善至 28.9%，显示出更好的财务健康和降低的杠杆风险。最近，Kamei 宣布了一项 40 亿日元的股份回购计划，以提升股东价值并适应市场变化；这一举措反映了对未来前景的信心和资本管理的战略灵活性。</p>
</div><ul>
<li>Navigate through the intricacies of Kamei with our comprehensive health report here.</li>
<li>Evaluate Kamei's historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的综合健康报告深入了解 Kamei 的复杂性。</li>
<li>通过访问我们的历史表现报告评估 Kamei 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc868fea-bc7d-4c3b-ad20-a91f73bb57cd/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/dc868fea-bc7d-4c3b-ad20-a91f73bb57cd/chart/debt-equity-history-analysis"/></p>
<p>TSE:8037 Debt to Equity as at Feb 2025</p>
<div class="lb-trans"><p>TSE:8037 截至 2025 年 2 月的债务与股本比率</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Unlock our comprehensive list of 4699 Undiscovered Gems With Strong Fundamentals by clicking here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里解锁我们包含 4699 个具有强大基本面的未被发现的投资机会的综合列表。</li>
<li>已经拥有这些公司？通过将您的投资组合与 Simply Wall St 连接，清晰化您的投资决策，您可以轻松监控所有股票的关键指标。</li>
<li>使用 Simply Wall St 应用程序提升您的投资能力，享受跨越每个大洲的市场情报的免费访问。</li>
</ul>
</div><h2>Seeking Other Investments?</h2>
<div class="lb-trans"><h2>寻找其他投资？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div>

未被发现的宝石以及另外两个具有潜力的小盘股